We are live on ! Find out more
EVGN icon

Evogene

18 hedge funds and large institutions have $200K invested in Evogene in 2025 Q4 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 7 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 1

29% more funds holding

Funds holding: 1418 (+4)

14% more capital invested

Capital invested by funds: $176K → $200K (+$23.8K)

86% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 7

Holders
18
Holders Change
+4
Holders Change %
+28.57%
% of All Funds
0.22%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
5
Increased
1
Reduced
7
Closed
1
Calls
Puts
Net Calls
Net Calls Change

EVGN Hedge Fund Activity: Q4 2025 in Review

18 of the 8,228 institutional investors tracked by Wall St. Rank reported a position in Evogene (EVGN) for Q4 2025, worth a combined $200K — up 14% from $176K a quarter earlier.

Buyers outnumbered sellers: 5 funds opened new EVGN positions and 1 closed out — a net gain of 4 holders — while 1 added to existing stakes and 7 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $36.4K. The largest seller was Morgan Stanley, cutting an estimated $24.8K.

  • 18 institutional investors held Evogene (EVGN) as of Q4 2025, up from 14 in Q3 2025.
  • Funds reported $200K of Evogene stock for Q4 2025, up 14% quarter-over-quarter.
  • 5 funds opened new Evogene positions in Q4 2025 and 1 closed out, a net change of +4 holders.
  • The largest Evogene buyer in Q4 2025 was Citadel Advisors, an estimated $36.4K added.
  • The largest Evogene seller in Q4 2025 was Morgan Stanley, an estimated $24.8K sold.

Based on aggregated 13F filings for Q4 2025.